Ceftaroline versus vancomycin for methicillin-resistant Staphylococcus aureus bacteraemia, a matched cohort study

被引:0
|
作者
Bitterman, Roni [1 ]
Awwad, Aya [2 ]
Darawsha, Basel [2 ]
Dallashi, Hajar [3 ]
Dishon-Benattar, Yael [1 ,4 ]
Pollack, Dina [5 ]
Paul, Mical [1 ]
机构
[1] Rambam Hlth care Campus, Div Infect Dis, Haifa, Israel
[2] Technion Israeli Inst Technol, Fac Med, Haifa, Israel
[3] Rambam Hlth Care Campus, Internal Med B, Haifa, Israel
[4] Univ Haifa, Cheryl Spencer Dept Nursing, Haifa, Israel
[5] Rambam Hlth care Campus, Microbiol Lab, Haifa, Israel
关键词
COMMUNITY-ACQUIRED PNEUMONIA; PEDIATRIC-PATIENTS; INTEGRATED ANALYSIS; COMPLICATED SKIN; NON-INFERIORITY; PLUS AZTREONAM; RISK-FACTORS; DOUBLE-BLIND; MULTICENTER; FOSAMIL;
D O I
10.1093/jac/dkaf009
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Vancomycin remains the treatment-of-choice in MRSA bacteraemia (MRSAB) despite significant limitations. Objective: To compare the effectiveness of ceftaroline and vancomycin monotherapy as the initial targeted therapy for MRSAB. Methods: We conducted a retrospective matched cohort study. Consecutive adult patients treated with ceftaroline in the years 2019-2021 were matched in a 1:2 ratio with patients who received vancomycin. Controls were matched for performance of trans-oesophageal echocardiography, Charlson comorbidity index and age. The primary outcome was a composite of treatment failure, defined as 90-day mortality or microbiological failure. Descriptive statistics were used to compare the ceftaroline and vancomycin-treated groups. Univariate and multivariable binary logistic regression models were created using ceftaroline treatment as the exposure variable. Results: Forty-five patients treated with ceftaroline for MRSAB were matched with 83 patients who received vancomycin. The groups were well balanced with regards to demographics and clinical characteristics. The primary outcome of treatment failure occurred at a similar rate in patients treated with ceftaroline or vancomycin (51.1%, 23/45% versus 57.8%, 48/83, respectively, P = 0.47). In the multivariable analysis, only age (aOR 1.06, 95% CI 1.01-1.1, P = 0.02) was associated with treatment failure. Acute kidney injury was more common among patients treated with ceftaroline (51.1%, 23/45% versus 18.1%, 15/83, P < 0.001). Conclusions: Ceftaroline was not associated with improved outcomes compared to vancomycin when given as initial treatment for MRSAB, however, it appears to be a viable alternative to vancomycin. Larger studies are needed to provide definitive results and to elucidate the risk of nephrotoxicity.
引用
收藏
页码:848 / 856
页数:9
相关论文
共 50 条
  • [41] Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care ?
    Johnson, Tanner M.
    Molina, Kyle C.
    Miller, Matthew A.
    Kiser, Tyree H.
    Huang, Misha
    Mueller, Scott W.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (04)
  • [42] Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review
    Cosimi, Reese A.
    Beik, Nahal
    Kubiak, David W.
    Johnson, Jennifer A.
    OPEN FORUM INFECTIOUS DISEASES, 2017, 4 (02):
  • [43] Pharmacokinetics of Ceftaroline in a Preterm Infant With Methicillin-Resistant Staphylococcus Aureus Pneumonia
    Salerno, Sara N.
    Bernhardt, Janice
    Laughon, Matthew
    Jhaveri, Ravi
    Massaro, Matthew
    Gonzalez, Daniel
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2018, 7 (04) : 342 - 345
  • [44] Molecular study of methicillin-resistant Staphylococcus aureus bacteraemia in a tertiary care hospital
    Platsouka, E.
    Kraniotaki, E.
    Belesiotou, E.
    Argyropoulou, A.
    Perivolioti, E.
    Paniara, O.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S620 - S620
  • [45] Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline
    Mendes, Rodrigo E.
    Tsakris, Athanassios
    Sader, Helio S.
    Jones, Ronald N.
    Biek, Donald
    McGhee, Pamela
    Appelbaum, Peter C.
    Kosowska-Shick, Klaudia
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (06) : 1321 - 1324
  • [46] Molecular Mechanisms of Ceftaroline Susceptibility Reduction in Methicillin-Resistant Staphylococcus aureus
    Gostev, V. V.
    Kalinogorskaya, O. S.
    Dmitrenko, O. A.
    Tsvetkova, I. A.
    Sidorenko, S., V
    ANTIBIOTIKI I KHIMIOTERAPIYA, 2016, 61 (9-10) : 17 - 21
  • [47] Ceftaroline: A Novel Cephalosporin with Activity against Methicillin-resistant Staphylococcus aureus
    Saravolatz, Louis D.
    Stein, Gary E.
    Johnson, Leonard B.
    CLINICAL INFECTIOUS DISEASES, 2011, 52 (09) : 1156 - 1163
  • [48] In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus isolates
    Basireddy, S.
    Singh, M.
    Ali, S.
    Kabra, V.
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2015, 33 (03) : 464 - +
  • [49] Ceftaroline Fosamil: A Cephalosporin With Activity Against Methicillin-Resistant Staphylococcus Aureus
    Poon, Henry
    Chang, Mei H.
    Fung, Horatio B.
    CLINICAL THERAPEUTICS, 2012, 34 (04) : 743 - 765
  • [50] Evaluation of the synergistic effect of ceftaroline against methicillin-resistant Staphylococcus aureus
    Tsai, Cheng-En
    Yang, Chia-Jui
    Chuang, Yu-Chung
    Wang, Jann-Tay
    Sheng, Wang-Huei
    Chen, Yee-Chun
    Chang, Shan-Chwen
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 122 : 230 - 236